Early Treatment of Stroke With Monosialoganglioside GM‐1: Efficacy and Safety Results of the Early Stroke Trial

@article{Lenzi1994EarlyTO,
  title={Early Treatment of Stroke With Monosialoganglioside GM‐1: Efficacy and Safety Results of the Early Stroke Trial},
  author={Gian Luigi Lenzi and Francesco Grigoletto and Michael Gent and Robin S. Roberts and Michael D. Walker and J. Donald Easton and Antonio Carolei and Frank Charles Dorsey and Walter A. Rocca and R. Bruno and Francesca Patarnello and Cesare Fieschi},
  journal={Stroke},
  year={1994},
  volume={25},
  pages={1552–1558}
}
Background and Purpose The Early Stroke Trial (EST) is a randomized, double-blind, placebo-controlled trial to assess the effect of monosialoganglioside GM-1 in improving recovery in patients who experienced an ischemic supratentorial stroke. Methods Sixteen clinical centers recruited 805 patients, of whom 792 were confirmed to be eligible. Treatment, consisting of a first dose of either 200 mg GM-1 or placebo, was initiated within 5 hours of the onset of stroke; a second dose of either 100 mg… 

Tables from this paper

Lubeluzole in Acute Ischemic Stroke Treatment
TLDR
This study failed to show an efficacy of lubeluzole in the treatment of acute stroke, and lubELuzole treatment by the current dosage schedule was not associated with a significant safety problem.
The Sygen® Multicenter Acute Spinal Cord Injury Study
TLDR
Although not proven in the primary efficacy analysis of this trial, Sygen® appears to be beneficial in patients with severe spinal cord injury.
Lubeluzole in Acute Ischemic Stroke Treatment: A Double-Blind Study With an 8-Hour Inclusion Window Comparing a 10-mg Daily Dose of Lubeluzole With Placebo
TLDR
This study failed to show an efficacy of lubeluzole in the treatment of acute stroke, and lubELuzole treatment by the current dosage schedule was not associated with a significant safety problem.
GM1 ganglioside treatment of Parkinson's disease
TLDR
It is suggested that GM1 ganglioside is well tolerated and may be a useful adjunct to the treatment of PD, and that a double-blind, placebo-controlled study is now warranted.
ECASS : LESSONS FOR FUTURE THROMBOLYTIC STROKE TRIALS
TLDR
ECASS is the first large, randomized, blinded study of high-dose intravenous recombinant tissue plasminogen activator (rt-PA) designed to determine if this thrombolytic therapy is efficacious and safe in acute stroke patients.
Clinical trials for cytoprotection in stroke
TLDR
This review will focus on individual therapeutic strategies and will emphasize what the authors have learned from these trials both in terms of trial design and the biologic effect (or lack thereof) of these agents.
Gangliosides for acute ischaemic stroke.
TLDR
There is not enough evidence to conclude that gangliosides are beneficial in acute ischaemic stroke, and caution is warranted because of reports of sporadic cases of Guillain-Barré syndrome afterganglioside therapy.
Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke
TLDR
The results suggest that CEGI has an effective neuroprotective effect on ischemic stroke when administered after the time window of thrombolysis.
Neuroprotection as Initial Therapy in Acute Stroke
TLDR
The only firm guideline than can be proposed for patient selection is the need for early admission to enable neuroprotectant and/or thrombolytic treatment to be started as soon as possible within the therapeutic window, and more experimental data are needed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Design and Baseline Results of the Monosialoganglioside Early Stroke Trial
TLDR
This study demonstrates the feasibility of large-scale trials with the onset of treatment within 5 hours after an ischemic stroke.
Clinical Trial of Nimodipine in Acute Ischemic Stroke
TLDR
Nimodipine had no overall effect when treatment was begun within 48 hours and post hoc subgroup analysis showed a reduction in worsening frequency of 30% compared with placebo and significantly better outcome scores with 120 mg nimmodipine daily started within 18 hours of stroke.
Monosialoganglioside in subarachnoid hemorrhage.
TLDR
The results seem to confirm the hypothesis that monosialoganglioside reduces brain edema and provides nonspecific neuronal membrane protection in patients with disturbance of consciousness following subarachnoid hemorrhage.
Monosialoganglioside GM1 in cerebral ischemia.
TLDR
It appears likely that GM1 protective effects in the acute injury phase are at least in part due to the attenuation of excitotoxicity, while the long-term functional recovery might reflect GM1 potentiation of neuronotrophic factors.
Thrombolytic therapy for stroke
TLDR
Results of randomized trials will be important in clarifying any cause-effect relationships between thrombolytic therapy and symptomatic and asymptomatic intracranial hemorrhage and clinical benefit will depend on the results of multicenter randomized trials that should available in 1995.
An analysis of time of presentation after stroke.
TLDR
A majority of patients may not be candidates for some therapies for acute stroke because of this delay in presentation, and reasons for this delay may include patients' lack of awareness about the symptoms of stroke and lack of recognition of early signs by medical personnel.
Ganglioside therapy and Guillain-Barré syndrome. A historical cohort study in Ferrara, Italy, fails to demonstrate an association.
TLDR
This study suggests that patients receiving gangliosides are not at increased risk of developing Guillain-Barré syndrome, but because of sample size limitations, these findings should be confirmed in a larger cohort study.
Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia.
TLDR
It is suggested that 3-4 hours of focal cerebral ischemia in this rat model is sufficient to attain maximal infarction and suggest that recirculation or pharmacological interventions after this time will provide little benefit.
...
1
2
3
...